Eli Lilly (NYSE:LLY) will collaborate with Oxford, England-based Evox Therapeutics
on potential treatments of neurological disorders. The partnership will
leverage Evox’s proprietary DeliverEX platform to develop RNA
interference and antisense oligonucleotide drug payloads for up to five
targets.
Evox will be responsible for exosome engineering
aimed at brain/CNS targeting, drug loading and analytics and some in
vitro assay development. Lilly will take over after the completion of
preclinical proof-of-concept studies.
Lilly will pay Evox $20M upfront, research funding
for three years, up to $1.2B in milestones and tiered royalties up to
low double digits on net sales. Lilly will also invest $10M in Evox in
exchange for a convertible bond.
https://seekingalpha.com/news/3581471-lilly-teams-up-evox-therapeutics-in-neurological-disorders
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.